Abstract
Allogeneic hematopoietic stem cell transplantation is the only curative treatment for patients with the non-malignant bone marrow failure syndrome called Fanconi anemia (FA). However, early and late complications associated with this approach underscore the need for alternative treatments. Gene therapy approaches aiming to correct the genetic defect in the patient’s own hematopoietic stem cells remain the most promising strategy to overcome FA-associated bone marrow failure. Yet, despite more than two decades of clinical research, a therapeutic “success” has not yet been achieved. Here we review the clinical trials conducted to date and highlight the unique features of FA revealed by these studies. These features render FA the “holy grail” of hematopoietic stem cell gene therapy approaches, and identify the future steps required to achieve clinical success in this rare disease.
Keywords: Fanconi anemia, Clinical trials, Gene therapy, Bone marrow failure, Stem cells, Viral vectors.
Current Gene Therapy
Title:Lessons Learned from Two Decades of Clinical Trial Experience in Gene Therapy for Fanconi Anemia
Volume: 16 Issue: 5
Author(s): Jennifer E. Adair, Julian Sevilla, Cristina Diaz de Heredia, Pamela S. Becker, Hans-Peter Kiem and Juan Bueren
Affiliation:
Keywords: Fanconi anemia, Clinical trials, Gene therapy, Bone marrow failure, Stem cells, Viral vectors.
Abstract: Allogeneic hematopoietic stem cell transplantation is the only curative treatment for patients with the non-malignant bone marrow failure syndrome called Fanconi anemia (FA). However, early and late complications associated with this approach underscore the need for alternative treatments. Gene therapy approaches aiming to correct the genetic defect in the patient’s own hematopoietic stem cells remain the most promising strategy to overcome FA-associated bone marrow failure. Yet, despite more than two decades of clinical research, a therapeutic “success” has not yet been achieved. Here we review the clinical trials conducted to date and highlight the unique features of FA revealed by these studies. These features render FA the “holy grail” of hematopoietic stem cell gene therapy approaches, and identify the future steps required to achieve clinical success in this rare disease.
Export Options
About this article
Cite this article as:
Adair E. Jennifer, Sevilla Julian, Heredia Diaz de Cristina, Becker S. Pamela, Kiem Hans-Peter and Bueren Juan, Lessons Learned from Two Decades of Clinical Trial Experience in Gene Therapy for Fanconi Anemia, Current Gene Therapy 2016; 16 (5) . https://dx.doi.org/10.2174/1566523217666170119113029
DOI https://dx.doi.org/10.2174/1566523217666170119113029 |
Print ISSN 1566-5232 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5631 |
Call for Papers in Thematic Issues
Programmed Cell Death Genes in Oncology: Pioneering Therapeutic and Diagnostic Frontiers (BMS-CGT-2024-HT-45)
Programmed Cell Death (PCD) is recognized as a pivotal biological mechanism with far-reaching effects in the realm of cancer therapy. This complex process encompasses a variety of cell death modalities, including apoptosis, autophagic cell death, pyroptosis, and ferroptosis, each of which contributes to the intricate landscape of cancer development and ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Transcriptional Control of the Oxidative Stress Response and Implications
of Using Plant Derived Molecules for Therapeutic Interventions
in Cancer
Current Medicinal Chemistry Efficacy and Safety of EGFR Inhibitors in the Treatment of EGFRPositive NSCLC Patients: A Meta-Analysis
Reviews on Recent Clinical Trials CYP Epoxygenase Derived EETs: From Cardiovascular Protection to Human Cancer Therapy
Current Topics in Medicinal Chemistry Voltage-Dependent Potassium Channels Kv1.3 and Kv1.5 in Human Cancer
Current Cancer Drug Targets Efficient Gene Selection for Cancer Prognostic Biomarkers Using Swarm Optimization and Survival Analysis
Current Bioinformatics Hypericin Lights Up the Way for the Potential Treatment of Nasopharyngeal Cancer by Photodynamic Therapy
Current Clinical Pharmacology Medical Expert Systems
Current Bioinformatics Advances Towards The Discovery of GPR55 Ligands
Current Medicinal Chemistry Small Molecule Drugs and Targeted Therapy for Melanoma: Current Strategies and Future Directions
Current Medicinal Chemistry Based on Nucleotides Analysis of Tumor Cell Lines to Construct and Validate a Prediction Model of Mechanisms of Chemotherapeutics
Anti-Cancer Agents in Medicinal Chemistry NF-κB Inhibitors in Head and Neck Cancer
Letters in Drug Design & Discovery Alternative Splicing, DNA Damage and Modulating Drugs in Radiation Therapy for Cancer
Anti-Cancer Agents in Medicinal Chemistry Anti-VEGF/VEGFR2 Monoclonal Antibodies and their Combinations with PD-1/PD-L1 Inhibitors in Clinic
Current Cancer Drug Targets Volatilome Metabolomics and Databases, Recent Advances and Needs
Current Metabolomics Cationic Liposomes for Gene Delivery: Novel Cationic Lipids and Enhancement by Proteins and Peptides
Current Medicinal Chemistry Notch Signalling Pathways and Their Importance in the Treatment of Cancers
Current Drug Targets Knockdown of Insulin-Like Growth Factor I Receptor Inhibits the Growth and Enhances Chemo-Sensitivity of Liver Cancer Cells
Current Cancer Drug Targets Antibody-Dependent Cell-Mediated Cytotoxicity Through Natural Killer (NK) Cells: Unlocking NK Cells for Future Immunotherapy
Current Pharmaceutical Biotechnology The Intriguing Interplay Between Therapies Targeting the Epidermal Growth Factor Receptor, the Hypoxic Microenvironment and Hypoxia-inducible Factors
Current Pharmaceutical Design Small Molecule Integrin Antagonists in Cancer Therapy
Mini-Reviews in Medicinal Chemistry